Clinical, demographic and genetic features of patients with congenital heart disease : A single center experience

Year 2022, Volume: 35 Issue: 2, 159 - 163, 30.05.2022

Hande Kaymakcalan Leyla Yalcınkaya Emrah Nıkerel Yalim Yalcın Weilai Dong Adife Gulhan Ercan Sencıcek

https://doi.org/10.5472/marumj.1120570

Abstract

Objective: We aimed to evaluate the demographic and clinical characteristics of children with congenital heart disease (CHD) in a
private pediatric cardiovascular genetics clinic in Istanbul from January 2016 to July 2018 and increase the awareness and emphasize
the importance of genetic counseling in CHD.

Patients and Methods: One hundred and seventeen patients (50 female, 67 male) from 3 days of age to 25 years of age in 17 months
period ( January 2016 to July 2018) were retrospectively analyzed. Data included age, sex, echocardiography results, extracardiac
features, genetic test results, consanguinity and any family member with heart disease. Pearson’s chi-squared test with 1 degree of
freedom and 5% significance was used for correlations.

Results: Consanguinity rate was 23.9%. Most common diagnosis was Tetralogy of Fallot (TOF) followed by atrial septal defect (ASD)
and ventricular septal defect (VSD) equally. 30 patients had genetic testing which revealed a diagnosis in 36.6 % of the patients. 6
patients had DiGeorge, one had Renpenning,one had Kabuki syndrome. We had one NODAL, one MYH7 and one MYH6 variant.

Conclusion: Genetic testing in CHD has a high diagnostic yield. Genetic counseling can help diagnostic, prognostic, and therapeutic
and family planning decision making.

Keywords

Congenital heart disease, Genetics, Genetic counseling

References

• [1] van der Linde D, Konings EEM, Slager MA, et al. Birth prevalence of congenital heart disease worldwide. J Am Coll Cardiol 2011; 58:2241-7. doi: 10.1016/j.jacc.2011.08.025
• [2] Jin SC, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet 2017; 49:1593-601. doi: 10.1038/ng.3970
• [3] Homsy J, Zaidi S, Shen Y, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science 2015; 350:1262-6. doi: 10.1126/ science.aac9396
• [4] Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature 2013; 498:220-3. doi: 10.1038/nature12141
• [5] Blue GM, Kirk EP, Giannoulatou E, et al. Advances in the genetics of congenital heart disease. J Am Coll Cardiol 2017; 69:859-70. doi: 10.1016/j.jacc.2016.11.060
• [6] Geddes GC, Earing MG. Genetic evaluation of patients with congenital heart disease. Curr Opin Pediatr 2018;30:707-13. doi: 10.1097/MOP.000.000.0000000682
• [7] Hacettepe University Institute of Population Studies. 2018 Turkey Demographic and Health Survey. Hacettepe University Institute of Population Studies, T.R. Presidency of Turkey Directorate of Strategy and Budget and TÜBİTAK, Ankara, Turkey 2019.
• [8] Miller DT, Adam MP, Aradhya S, et al. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86:749-64. doi: 10.1016/j. ajhg.2010.04.006
• [9] Kung GC, Chang PM, Sklansky MS, Randolph LM. Hypoplastic left heart syndrome in patients with Kabuki syndrome. Pediatr Cardiol 2010; 31:138-41. doi: 10.1007/s00246.009.9554-7
• [10] Granados-Riveron JT, Ghosh TK, Pope M, et al. α-Cardiac myosin heavy chain (MYH6) mutations affecting myofibril formation are associated with congenital heart defects. Hum Mol Genet 2010; 19:4007-16. doi: 10.1093/hmg/ddq315
• [11] Sabater-Molina M, Pérez-Sánchez I, Hernández del Rincón JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin Genet 2018; 93:3-14. doi: 10.1111/ cge.13027
• [12] Hassel D, Dahme T, Erdmann J, et al. Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy. Nat Med 2009; 15:1281-8. doi: 10.1038/nm.2037
• [13] Mohapatra B, Casey B, Li H, et al. Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. Hum Mol Genet 2009; 18:861-71. doi: 10.1093/hmg/ddn411
• [14] Botto LD, May K, Fernhoff PM, et al. A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 2003; 112:101-7. doi:10.1542/peds.112.1.101
• [15] Cancrini C, Puliafito P, Digilio MC, et al. Clinical features and follow-up in patients with 22q11.2 deletion syndrome. J Pediatr 2014; 164:1475-80. doi: 10.1016/j.jpeds.2014.01.056
• [16] Pierpont ME, Brueckner M, Chung WK, et al. Genetic basis for congenital heart disease: Revisited: A scientific statement from the American Heart Association. Circulation 2018; 138:653-711. doi: 10.1161/CIR.000.000.0000000606
• [17] Goldmuntz E. 22q11.2 deletion syndrome and congenital heart disease. Am J Med Genet C Semin Med Genet 2020; 184:64-72. doi: 10.1002/ajmg.c.31774
• [18] Morales-Demori R. Congenital heart disease and cardiac procedural outcomes in patients with trisomy 21 and Turner syndrome. Congenit Heart Dis 2017; 12:820-7. doi: 10.1111/ chd.12521
• [19] White BR, Rogers LS, Kirschen MP. Recent advances in our understanding of neurodevelopmental outcomes in congenital heart disease. Curr Opin Pediatr 2019; 31:783-8. doi: 10.1097/ MOP.000.000.0000000829